Deutsche Bank Aktiengesellschaft Forecasts Strong Price Appreciation for AstraZeneca (LON:AZN) Stock

AstraZeneca (LON:AZN) had its price target hoisted by stock analysts at Deutsche Bank Aktiengesellschaft from £117 to £120 in a research note issued to investors on Friday, Digital Look reports. The brokerage presently has a “hold” rating on the biopharmaceutical company’s stock. Deutsche Bank Aktiengesellschaft‘s target price would indicate a potential downside of 14.98% from the stock’s previous close.

Other equities analysts have also issued research reports about the stock. Royal Bank Of Canada initiated coverage on shares of AstraZeneca in a report on Tuesday, September 8th. They issued an “outperform” rating and a £145 price target on the stock. Citigroup upped their price objective on AstraZeneca from £175 to £178 and gave the stock a “buy” rating in a report on Tuesday, July 28th. Jefferies Financial Group reaffirmed a “buy” rating and issued a £175 target price on shares of AstraZeneca in a research report on Friday, October 30th. Finally, Berenberg Bank reaffirmed a “buy” rating and issued a £175 target price on shares of AstraZeneca in a research report on Wednesday, October 7th. Six analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, AstraZeneca presently has an average rating of “Moderate Buy” and an average price target of £155.50.

AstraZeneca Stock Performance

Shares of AZN stock opened at £141.15 on Friday. AstraZeneca has a one year low of £114.04 and a one year high of £157.32. The company has a debt-to-equity ratio of 66.10, a quick ratio of 0.59 and a current ratio of 1.01. The company has a 50 day moving average price of £124.76 and a 200 day moving average price of £134.29. The firm has a market capitalization of £218.91 billion, a price-to-earnings ratio of 19.99, a price-to-earnings-growth ratio of 0.86 and a beta of 0.21.

Insider Transactions at AstraZeneca

In related news, insider Michel Demare purchased 2,500 shares of the stock in a transaction that occurred on Monday, September 14th. The stock was purchased at an average cost of £121.21 per share, for a total transaction of £303,025. Corporate insiders own 0.15% of the company’s stock.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.